Outlook Therapeutics Inc
OTLK
Market Cap$376.78M
Close$
$-0.97
111.4% downside
Current Fair Value
111.4% downsideOvervalued by 111.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $376.78 Million |
|---|---|
| Enterprise Value | $357.50 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.0 |
| Beta | 0.0 |
| Outstanding Shares | 21,584,256 |
| Avg 30 Day Volume | 477,364 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.59 |
|---|---|
| PEG | 10.43 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 61.07 |
| Enterprise Value to EBIT | -12.9 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
ESG Score
No data
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon